Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Holders of 5% or more of PASG
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Passage BIO, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 13G/A | 19.60%623.7K shares | +4.60 ppfrom 15.00% | Feb 14, 20252 filings | Nov 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
9 Schedule 13D and 13G filings on Passage BIO, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 20252:01 PM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 19.60%623.7K shares | +4.60 ppfrom 15.00% | Sep 30, 2025 | SEC |
| Jul 24, 20255:44 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 4.25%132.5K shares | −3.57 ppfrom 7.82%Below 5% | Jul 22, 2025 | SEC |
| Jul 21, 20255:28 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 7.82%243.9K shares | −1.68 ppfrom 9.50% | Jul 17, 2025 | SEC |
| Jul 9, 20258:06 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 9.50%5.92M shares | −1.20 ppfrom 10.70% | Jul 7, 2025 | SEC |
| Apr 25, 20257:48 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 10.70%6.65M shares | −1.30 ppfrom 12.00% | Apr 22, 2025 | SEC |
| Feb 14, 20259:01 AM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 15.00%9.26M shares | – | Dec 31, 2024 | SEC |
| Dec 26, 20244:31 PM ET | OrbiMed Advisors LLCand 2 others | 13D/A | 12.00%7.40M shares | – | Dec 20, 2024 | SEC |
| Nov 14, 20245:21 PM ET | Erste Asset Management GmbH | 13G/A | 4.42%2.46M shares | −0.98 ppfrom 5.40%Below 5% | Mar 31, 2024 | SEC |
| Nov 14, 20245:01 PM ET | Erste Asset Management GmbH | 13G | 5.40%2.96M shares | New | Dec 31, 2023 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Passage BIO, Inc. shares.
No Form 144 notices for Passage BIO, Inc. are on file.